Jan 17 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short ...
The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including ...
Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...